LB Pharma strengthens leadership team with key appointments

New York-based clinical-stage biotech LB Pharmaceuticals (Nasdaq: LBRX) has announced the appointments of Ellen Rose as senior vice president, corporate affairs and Lindsay Beaupre as SVP people and culture.

“We are pleased to welcome Ellen and Lindsay to LB Pharmaceuticals,” said Heather Turner, chief executive, adding: “Ms Rose has extensive experience in corporate communications, investor relations, and patient advocacy within the biopharma industry. Ms. Beaupre is a seasoned corporate builder and strategist, driving the implementation of organizational best practices and supporting organizational and cultural growth. We expect both to make strong contributions as we pursue development of LB-102, a novel benzamide for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.”

Ms Rose is a strategic communications executive with deep expertise spanning corporate affairs and investor relations, including external and internal communications, media, patient advocacy, and government affairs. Prior to joining LB Pharmaceuticals,